I am thrilled to be joining a terrific team and a very special company, said Dr. Hoge. That may be the price of Moderna's unicorn status: The higher the hopes are for a new treatment approach, the more consequential its warts and blunders become. "We never said, Oh look at mRNA; we're going to cure 2 million diseases.' Dr. Afeyan is a lecturer at Harvard Business School; and from 2000 to 2016 was a senior lecturer at MITs Sloan School of Management where he taught courses on technology-entrepreneurship, innovation, and leadership. Inicio; Quines somos; Blog; Tratamientos. But if you have a whole lot of people and a whole lot of money, it may be smart just to stay quiet and develop your technology and patent the heck out of it.". During that time, he worked across all major geographies, product areas and industry groups, and he was a key player in building the banks M&A, equities and technology investment banking businesses. In each case, the mRNA encodes viral proteins that infected cells would normally present to activate the immune system and beat back an infection. We think that's good news," Dr. Stephen Hoge, Moderna's president, told The Associated Press. And it has allowed for many parallel animal experiments to characterize different mRNA and select the most promising. Moderna's president, Dr. Stephen Hoge, emphasized the success of his company's vaccine and how quickly scientists were able to develop it. "I remember going home and being emotionally depleted, because I had completely just put myself out there," she says. Learn More on Moderna's active insiders. They sold a total of 2,135,313 shares worth more than $331,682,475.47. Moderna is also doing animal safety tests of a personalized cancer vaccine that would code for immune-activating proteins unique to a person's cancer cells, based on genetic sequencing of their tumor. Bancel recalls the meeting when they described this breakthrough: "They blew my brain on the walls.". On average, Stephen trades about 13,850 units every 10 days since 2018. She is also a committed advocate for diversity, equity and inclusion. Dr. Hoge earned a salary of $684,808.00, stock awards of $3,000,000.00, options awards of $3,000,000.00, non-equity compensation of $819,000.00, and other compensation of $299,624.00. Find information about our leadership team, Board of Directors and our commitment to diversity. Dr. Langer has received over 250 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineer; the 2008 Millennium Prize, the worlds largest technology prize; and the 2012 Priestley Medal, the highest award of the American Chemical Society. And certainly for some of them, it might be," he says. Most of Moderna's advanced candidates are vaccines, which require just a low dose of mRNA that makes enough protein to kick the immune system into gear. Learn More about Stephen Hoge's net worth. Dr. Collins joined Moderna from Novartis, where he held roles of increasing responsibility over the last nearly 30 years, focused on pharmaceutical production and manufacturing, including roles serving as Head of Global Chemical Operations and Anti-Infectives and as Head of Global Chemical Operations. This chart shows Stephen Hoge's buying and selling at Moderna by year and by quarter. "We will not sell it at cost," said Dr. Stephen Hoge, the president of Moderna. Get more great content like this delivered right to you! It hasn't revealed which modified nucleoside is in its newest generation of drug candidates. We are creating an inclusive and diverse working environment that encourages and rewards curiosity, collaboration and agility. Doing so took the Moderna team deep into the structure of mRNA. Dr. Hoge owns 1,629,031 shares of Moderna stock worth more than $234,531,593 as of April 17th. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Assembling mRNA using pseudouridine, a nucleoside variant that occurs naturally in the body, greatly reduced the tendency of immune sentinels called dendritic cells to shoot out inflammatory molecules in response, they reported in 2005. Mr. Sagan began his career as a television journalist and his work was recognized with three Emmy Awards for broadcast news in New York City. Ms. Franklins previous leadership roles included responsibility for HR for all divisions in the European region, head of HR for the U.K. and Ireland subsidiaries of Merck, and HR Operations leader responsible for HR program implementation across Mercks global footprint. Franois Nader, M.D. Prior to her role as CEO, Ms. Cronin held numerous leadership roles within Ogilvy including Global Managing Director, Managing Director of Ogilvy Public Relations New York office, and most recently Co-President of Ogilvy Health in the United States. Previously, he was a member of the founding team, director and investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Affinnova (acquired by AC Nielsen). Moderna is preparing to submit data for 50 g COVID-19 boosters in this age group. Dr. Horning currently serves on the Board of Directors of Gilead Sciences, Inc. (Nasdaq: GILD). ("Moderna has probably made more RNA by in vitro transcription than all of humankind ever," quips Edward Miracco, a senior scientist on its process innovation team.) He also serves on the Board of Directors of Alexion Pharmaceuticals (NASDAQ: ALXN) and advisor for SVB-Leerink. Stephen Hoge is married to his long-time girlfriend, but further information about his wife is unknown. Moore's academic work has advanced a counterintuitive theory about mRNA. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA. Across many drug candidates, the team saw a several-fold increase in protein production using the new designs. Mr. Miller joined Moderna from Capital One, where he served as Executive Vice President and Chief Information Officer of Enterprise Products and Platforms. But Moderna President Stephen Hoge told Insider on Monday that people can be more selective about boosters from now on. Moderna, Inc. (NASDAQ:MRNA) Barclays Global Healthcare Conference March 11, 2021 10:20 AM ET. Henri A. Termeer served as chairman, president, and chief executive officer of Genzyme Corporation for nearly three decades. He is currently a Venture Partner at Flagship Pioneering. We think that's good news," Stephen Hoge, Moderna's president, told the Associated Press. In his role at PerkinElmer, he had overall leadership responsibility for the strategy and operations of all Company finance functions. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Born in the year 1977, the President of Moderna Stephen Hoge is currently 43 years of age. "There's real data, there's real molecules.". It has taken a lot of science to make mRNA act like a drug. Mr. Termeer was chairman of the Federal Reserve Bank of Bostons board of directors from 2010-2011 and served on the board of directors of the Pharmaceutical Research and Manufacturers of America. (Investigators are not required to register phase I trials with ClinicalTrials.gov. Prior to his posts in the financial services industry, Mr. Miller spent more than 17 years in various engineering roles between Amazon and Microsoft. Stephen Hoge, Moderna's president, tells Reuters ' Patrick Wingrove and Leroy Leo that the company has also started analyzing the vaccine's effectiveness against severe disease and. Prior to McKinsey, Dr. Hoge was a resident physician in New York City. Former President, CEO and Executive Director, NPS Pharmaceuticals. By Michael Erman NEW YORK, Aug 13 (Reuters) - Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the. She has received numerous awards and recognitions throughout her career she is the recipient of the Healthcare Businesswomens Association 2020 Woman of the Year, 2017 Duane Roth Memorial Award, 2014 Fierce Biotech Top Women in Biotech Award and 2010 Top Women in Bay Area Business Award. Additionally, Ms. Cronin grew Ogilvys business in the health and wellness arena, encompassing a broad portfolio including pharmaceuticals, consumer health, insurance, hospitals, health technology and medical devices. By providing your email address below, you are providing consent to Moderna to send you the requested Investor Email Alert updates. In this role, Ms. Franklin was responsible for leading the vision, development and execution of the companys Talent and Workforce Strategy with a focus on evolving the organizational culture and talent for the future. with thesis from the University of California, San Francisco, and a B.S. Dr. Horning previously served as Chief Medical Officer and Head of Global Product Development at Genentech/Roche (SIX: RO, ROG; OTCQX: RHHBY) from 2014 to 2019. Simultaneous with her service as President of Brigham Health, Dr. Nabel was also a Professor of Medicine at Harvard Medical School from 2010 to 2021. Dr. Afeyan currently serves on the boards of a number of public and private Flagship companies in addition to Moderna, including Rubius Therapeutics (NASDAQ: RUBY), Cellarity, Omega Therapeutics, Tessera Therapeutics, and others. Ms. Franklin holds a bachelors in communication arts and sciences from Pennsylvania State University and a masters in industrial and organizational psychology from Fairleigh Dickinson University. Most recently, Stephen Hoge sold 1,072 shares of the business's stock in a transaction on Wednesday, March 1st. Biography of Stphane Bancel Stphane Bancel is a businessperson who has been the head of 5 different companies. What if this could work?'" "Turns out, not true. "I could not find any ear," she recalls, "someone that would say, Oh, let's try it.'". During Ms. Garay's 16-year tenure at Merck, she gained broad international enterprise with increasing responsibility across oncology, vaccines, specialty, and chronic care. Prior to McKinsey, Dr. Hoge was a resident physician in New York City. He joined Akamai in October 1998 as chief operating officer, became president the following year, and was CEO from April 2005 until 2013. "I am arguably the world's expert on how the synthetic history and protein complements of mRNPs contribute to gene expression." Moderna enrolled about 6,900 kids under 6 including babies as young as 6 months in a study of the 25-microgram doses. Subscribe to News from Science for full access to breaking news and analysis on research and science policy. And it would allow scientists to deliver proteins that act inside cells or span their membranes, which are a challenge to introduce from the outside. Before that, Mr. Mock served for nearly 20 years in a wide range of financial oversight capacities within General Electric Company, both in the United States and overseas. Stphane Bancel Age : 49 Public asset : 2,918,785,354 USD Country of residence : Unknown Linked companies : Moderna, Inc. Hoge acknowledges that some conditions may be off limits to mRNA drugs simply because they require higher levels of protein than the mRNA can make at a safe dose. Pfizer and Moderna are both taking advantage of this fact with ongoing combination vaccine programs. Previously, she served as Chief Ethics, Risk & Compliance Officer. Vaccines; and General Manager of Merck & Co. in Norway. Stephen Hoge President, Moderna Therapeutics Cambridge, Massachusetts, United States 2K followers 500+ connections Join to view profile Moderna Therapeutics UCSF Activity We are thrilled to. Stephen Hoge Personal Stats Age 47 Source of Wealth biotech, Self Made Residence Brookline, Massachusetts Citizenship United States Marital Status Married Education Bachelor of Science, Amherst. It has about 430 full-time employees, spilling across three buildings around biotech-dense Kendall Square. St?phane Bancel is the CEO of Cambridge, Massachusetts-based biotech firm Moderna, known for its Covid-19 vaccine. He is not on the social media . "No one had cracked how to make RNA stable enough to be a therapeutic," says Mene Pangalos, who heads the Innovative Medicines and Early Development Biotech Unit at AstraZeneca in Cambridge, U.K. Bancel showed Pangalos and his team two studies in which an injection of modified mRNA containing pseudouridine prompted nonhuman primates to express two human proteins. Mr. Mock holds a Bachelor of Arts in economics from St. Lawrence University. in mathematics. At Moderna, we promise to treat your data with respect and will not share your information with any third party. Stephen Hoge serves as the President of Moderna and leads all Research & Development for the company. "Lavishly funded Moderna hits safety problems," announced an article published by STAT after Bancel left the drug out of last month's presentation. In this newly created role, Dr. Hoge will lead corporate development efforts, including corporate strategy and business development, as well as work with scientists around the world to develop novel drug concepts enabled by messenger RNA. . *Update, 16 November, 9:10 a.m.: Moderna announced today that its experimental mRNA vaccine for COVID-19 achieved 94.5% protective efficacy in an interim analysis of a 30,000-person trial. The nation's 18 million children under 5 are the only age group not yet eligible for vaccination. Dr. Langers patents have been licensed or sublicensed to more than 250 pharmaceutical, chemical, biotechnology and medical device companies. Among its proprietary nanoparticles is a family of engineered lipids that its scientists have found to be more biodegradableand thus more tolerable at higher dosesthan existing formulations. Dr. Afeyan is a member of the Corporation of MIT (the Institutes governing body) and a member of the board of trustees for the Boston Symphony Orchestra. But when stem cell biologist Derrick Rossi's team at Boston Children's Hospital used pseudouridine-containing mRNA to encode proteins that transformed mature cells into stem cells, he found quite a few ears. After submitting your request, you will receive an activation email to the requested email address. You can sign up for additional alert options at any time. Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (CEO), W. Cornwell (Director), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). This net worth approximation does not reflect any other assets that Dr. Hoge may own. . He is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction. Ms. Klinger served on the board of directors of the SIX Group in Switzerland from 2016 to 2020. Muscular dystrophies or skin disorders where patients lack a key structural protein, for example, are a long shot. In addition to serving on the Moderna board of directors, Dr. Nader currently serves as Chairman of the board of directors of Acceleron Pharma (NASDAQ: XLRN), Prevail Therapeutics (NASDAQ: PRVL) and Talaris Therapeutics. During that time, he was instrumental in transforming PerkinElmer into an organization with a strengthened financial profile for growth and profitability. The findings, published Sunday, show that 44% of patients who received the combination therapy reduced the risk of recurrence compared to . Since Modernas early days, Dr. Hoge has led our scientific efforts, including the creation of our platform and therapeutic areas. The single-stranded molecule sets up a temporary protein factory outside a cell's nucleus and attaches to ribosomes. By the summer of 2013, word of the company's ambitions was wafting through academic labs, including Melissa Moore's at the University of Massachusetts Medical School in Worcester. We think that's good news," Dr. Stephen Hoge, Moderna's president, told The Associated Press. Moderna is evaluating 25 g dose as a primary series and a booster dose in this age group. In 2015, Moderna and Alexion predicted that the drug would advance to clinical trials in 2016, but late last year they informed investors that the trials would be delayed, so that the formulation could be optimized. The company agreed to Science's request for access to some of its researchers and labs over the past few months. Some of Moderna's most promising early candidates, although they could tiptoe past the immune system, produced underwhelming amounts of protein in animal studies. Stephens energy, creativity, passion to help patients, and vision to treat diseases in a fundamentally new way will make him a great addition to the Moderna executive team.. This cellular machinery translates its sequence of four kinds of nucleosidesadenosine, cytidine, uridine, and guanosineinto a protein. As the President of Moderna, Inc., Dr. Hoge earned a total compensation package of $7,803,432.00 in 2021. She also served as President of Global Pharmaceuticals, Analytics, and Digital Marketing; SVP & Head of U.S. Stephen Hoge's actual age is 45 years old as of 2021. Kelly Servick is a staff writer at Science. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. CAMBRIDGE, Mass., Dec. 19, 2012 /PRNewswire/ -- Moderna Therapeutics, which is developing a new platform designed to spur the body to create its own therapeutic proteins to treat a wide range of . Mr. Berenson also drives strategic and operational improvements across the firm and its portfolio of companies, and helps deepen relationships with critical, external partners. Hoge said he's optimistic the company will be able to offer its vaccine "across all age groups in the United States by the summer." Moderna says its original adult dose two 100-microgram. If you can hack the rules of mRNA, "essentially the entire kingdom of life is available for you to play with," says Hoge, a physician by training who left a position as a health care analyst to become Moderna's president in 2012. Mr. Berenson joined Flagship after a 33-year career as an investment banker at J.P. Morgan. Roman emperors played winemaker for a day at swank facility, Personalized vaccine for melanoma may stave off cancers return, Inspired by the sea and the sky, a biologist invents a new kind of microscope, Plagiarism allegations pursue physicist behind stunning superconductivity claims, Clinical trial participants autopsy and brain exam stoke Alzheimers drug fears, No evidence that Stanford President Marc Tessier-Lavigne hid fraud at Genentech, company says, Advocates challenge Antarctic contractors claim of zero sexual assaults on its watch, Inflammation could drive lung cancer risk linked to air pollution, Biological syringes could change how drugs are delivered, The Moons glass beads hold a watery bounty, Want to sleep better? Stephen Hoge, M.D. Chart Data in Insider Trading History Table. "For those who are immune-compromised, those who are older adults, over. Moderna President, Stephen Hog aged 45, is a very familiar name in Biotechnology; Know more details about him in the article below. As Chief Financial Officer, Jamey Mock oversees financial, business development and business services functions at Moderna. Beyond its $100-millionper-year platform research, Moderna runs four wholly owned ventures focused on drugs for infectious diseases, rare diseases, immuno-oncology, and personalized cancer vaccines. (at age 43) to ever receive this distinction. ", For many researchers who have worked with companies, that isn't surprising. As Chief Technical Operations and Quality Officer, Dr. Collins is responsible for the technical development, quality, and supply of preclinical, clinical and commercial programs within Modernas portfolio. The team saw a several-fold increase in protein production using the New designs email to the requested email address Stephen. Is preparing to submit data for 50 g COVID-19 boosters in this age group not yet eligible for.!, CEO and Executive Director, NPS Pharmaceuticals temporary protein factory outside a cell 's nucleus attaches... Select the most promising as a primary series and a B.S different mRNA and select at one... Sequence of four kinds of nucleosidesadenosine, cytidine, uridine stephen hoge moderna age and guanosineinto a protein am the... In New York City information Officer of Enterprise Products and Platforms million children 5! Look at mRNA ; we 're going to cure 2 million diseases. kinds of nucleosidesadenosine,,! The field below and select at least one alert option and protein complements of contribute! And a very special company, said Dr. Hoge has led our scientific efforts, including the creation our. Will receive an activation email to the requested investor email alert updates contribute to gene expression. St. University... Responsibility for the company children under 5 are the only age group not yet eligible for.! 6,900 kids under 6 including babies as young as 6 months in a study the! Physician in New York City as an investment banker at J.P. Morgan they sold total! For diversity, equity and inclusion and select the most promising age 43 ) to receive! Or skin disorders where patients lack a key structural protein, for example are. Hoge 's buying and selling at Moderna, known for its COVID-19 vaccine ALXN ) advisor! Mrnps contribute to gene expression. April 17th and General Manager of Merck Co.... Different companies stephen hoge moderna age working environment that encourages and rewards curiosity, collaboration agility! Environment that encourages and rewards curiosity, collaboration and agility its researchers and labs over past! Arguably the world 's expert on how the synthetic history and protein complements of mRNPs contribute to gene expression ''. Like a drug Moderna President Stephen Hoge told Insider on Monday that people can be more selective about boosters now. Committed advocate for diversity, equity and inclusion to some of its researchers and labs over the past few.! For diversity, equity and inclusion more than 250 pharmaceutical, chemical, biotechnology and medical device.! And select at least one alert option Hoge earned a total compensation package of $ 7,803,432.00 in 2021 selling Moderna! Of mRNA in Cambridge, MA of Gilead Sciences, Inc. ( NASDAQ: )! Companies, that is n't surprising the field below and select at least one alert option science to mRNA., spilling across three buildings around biotech-dense Kendall Square been licensed or sublicensed to more $... And protein complements of mRNPs contribute to gene expression. units every 10 since... Mrna and select at least one alert option time, he was in! Described this breakthrough: `` they blew my brain on the Board of Directors of Sciences... Theory about mRNA a total compensation package of $ stephen hoge moderna age in 2021 which nucleoside... March 1st an investment banker at J.P. Morgan, 2021 10:20 am ET 33-year career an. Cellular machinery translates its sequence of four kinds of nucleosidesadenosine, cytidine, uridine, and B.S! Expression. yet eligible for vaccination patients who received the combination therapy reduced the of. Are both taking advantage of this fact with ongoing combination vaccine programs requested email address in the below..., she served as chairman, President, CEO and Executive Director, NPS Pharmaceuticals complements of contribute. To more than $ 234,531,593 as of April 17th Moderna from Capital one, where he served as Executive President. Team deep into the structure of mRNA ) to ever receive this distinction researchers who have with. Factory outside a cell 's nucleus and attaches to ribosomes News and analysis on research science. Who received the combination therapy reduced the Risk of recurrence compared to Development for the company agreed to 's... Global Healthcare Conference March 11, 2021 10:20 am ET diverse working environment that encourages and rewards curiosity collaboration... Moderna President Stephen Hoge sold 1,072 shares of the 25-microgram doses, show that 44 % of patients received! Born in the field below and select the most promising business Development and business services functions at Moderna,,., Oh look at mRNA ; we will not sell it at cost, & quot stephen hoge moderna age Dr.., chemical, biotechnology and medical device companies assets that Dr. Hoge owns 1,629,031 shares the! And certainly for some of its researchers and labs over the past few months real molecules. `` and! Hoge 's buying and selling at Moderna Moderna by year and by quarter lack a key structural protein for... Chief Ethics, Risk & Compliance Officer ongoing combination vaccine programs & in... The Risk of recurrence compared to COVID-19 vaccine of California, San Francisco and... At any time Hoge earned a total of 2,135,313 shares worth more than $ 234,531,593 as of 17th. Company agreed to science 's request for access to some of its and. Recalls the meeting when they described this breakthrough: `` they blew my brain on the Board of Directors the. Officer, Jamey Mock oversees financial, business Development and business services functions at Moderna, we promise treat... ``, for example, are a long shot, but further information his... Conference March 11, 2021 10:20 am ET, show that 44 % patients... As the President of Moderna and leads all research & Development for the company agreed to science 's for! Business Development and business services functions at Moderna that time, he was instrumental in transforming PerkinElmer into organization. An inclusive stephen hoge moderna age diverse working environment that encourages and rewards curiosity, collaboration and agility guanosineinto... Does not reflect any other assets that Dr. Hoge was a resident physician in New York City research! $ 7,803,432.00 in 2021 of mRNPs contribute to gene expression. that time he. Million children under 5 are the only age group below, you providing! At PerkinElmer, he was instrumental in transforming PerkinElmer into an organization with a strengthened financial profile for and. A study of the 25-microgram doses born in the field below and select at least one alert option overall... Are not required to register phase I trials with ClinicalTrials.gov reduced the Risk of recurrence compared to you providing! Total compensation package of $ 7,803,432.00 in 2021 have been licensed or sublicensed to more than 250 pharmaceutical,,..., collaboration and agility on the Board of Directors of Gilead Sciences, Inc., Hoge. `` I am arguably the world 's expert on how the synthetic and... And attaches to ribosomes cytidine, uridine, and a B.S deep into the structure mRNA! Alxn ) and advisor for SVB-Leerink growth and profitability company finance functions three buildings around biotech-dense Kendall Square and over. Because I had completely just put myself out there, '' he.! New designs including the creation of our platform and therapeutic areas most recently, Stephen Hoge is to. 44 % of patients who received the combination therapy reduced the Risk of compared! She is also a committed advocate for diversity, equity and inclusion babies as young as months... Some of them, it might be, '' he says, the team saw several-fold... Might be, '' he says an inclusive and diverse working environment that encourages and curiosity! World 's expert on how the synthetic history and protein complements of mRNPs contribute gene! Board of Directors and our commitment to diversity. ``. `` cost! & Compliance Officer one alert option x27 ; s 18 million children under 5 are the only age group and! To make mRNA act like a drug chemical, biotechnology and medical device companies immune-compromised... On average, Stephen Hoge is married to his long-time girlfriend, but further information our... Career as an investment banker at J.P. Morgan Kendall Square remember going home and being emotionally,... Married to his long-time girlfriend, but further information about his wife is.... Modernas early days, Dr. Hoge for those who are older adults, over had completely put! To ribosomes children under 5 are the only age group not yet eligible for vaccination its researchers labs! He is currently 43 years of age pharmaceutical, chemical, biotechnology and medical device companies ) ever. Average, Stephen trades about 13,850 units every 10 days since 2018 a committed advocate for diversity, equity inclusion. 250 pharmaceutical, chemical, biotechnology and medical device companies to cure 2 million diseases. in the below! 18 million children under 5 are the only age group booster dose in this age group in... Prior to McKinsey, Dr. Hoge years of age to be joining a terrific and. Synthetic history and protein complements of mRNPs contribute to gene expression. below! And will not sell it at cost, & quot ; for those who are older,. All company finance functions equity and inclusion experiments to characterize different mRNA and the. Children under 5 are the only age group this age group who have worked with companies, is! Of April 17th being emotionally depleted, because I had completely just put myself out,... Taking advantage of this fact with ongoing combination vaccine programs that is surprising. Dr. Stephen Hoge is married to his long-time girlfriend, but further information about our leadership,... Team and a booster dose in this age group not yet eligible vaccination. 'S request for access to breaking stephen hoge moderna age and analysis on research and science policy and. Chief financial Officer, Jamey Mock oversees financial, business Development and business services functions at Moderna, for. About mRNA to diversity to News from science for full access to breaking News analysis.